Can I Take Folate with Lisinopril?

What the Evidence Says About Folate and Lisinopril Together

No head-to-head randomized trial has tested folate supplementation exclusively alongside lisinopril, but the pharmacological picture is clear enough to give practical guidance. The two agents work through entirely separate biochemical pathways. Lisinopril blocks angiotensin-converting enzyme, reducing angiotensin II and lowering vascular resistance. Folate participates in one-carbon metabolism, supporting DNA synthesis, amino-acid recycling, and the remethylation of homocysteine to methionine. These pathways do not share a common enzyme, transporter, or receptor, so competitive or additive toxicity is not expected.

Why "No Interaction" Needs Nuance

The absence of a harmful pharmacokinetic interaction does not mean folate is irrelevant to cardiovascular therapy. Elevated plasma homocysteine independently associates with endothelial dysfunction and increased cardiovascular risk. A 2012 meta-analysis published in JAMA Internal Medicine (N=37,485 across 8 trials) found that folic acid supplementation reduced homocysteine by approximately 25% and modestly lowered stroke risk [1]. Because lisinopril is prescribed heavily in patients who already carry elevated cardiovascular risk, the question of whether folate adds a protective signal in that same population is clinically meaningful.

Pharmacokinetic Details

Lisinopril is not metabolized by the cytochrome P450 system. It is absorbed in the small intestine and excreted renally, largely unchanged. Folate is absorbed through the proton-coupled folate transporter (PCFT/SLC46A1) and the reduced folate carrier (RFC) in the jejunum [2]. Because these absorption mechanisms are distinct, co-administration does not reduce the bioavailability of either compound. No dose-separation window is required.

Pharmacodynamic Overlap: A Potentially Beneficial Signal

Both folate and ACE inhibitors may independently improve endothelial function. A randomized crossover study published in Circulation (N=33 patients with coronary artery disease) found that 5 mg/day folic acid for 6 weeks improved flow-mediated dilation by 1.1 percentage points beyond placebo (P<0.01) [3]. Lisinopril similarly preserves nitric-oxide bioavailability by reducing oxidative degradation. The combination has not been formally studied for additive endothelial benefit, but mechanistic logic and the data in [3] suggest no antagonism.

How Lisinopril Works and Why Folate Status Matters

Lisinopril is a long-acting, non-prodrug ACE inhibitor approved by the FDA for hypertension, heart failure with reduced ejection fraction, and acute myocardial infarction with left ventricular dysfunction [4]. Its cardiovascular benefits are well-established: the GISSI-3 trial (N=19,394) demonstrated a 6-week all-cause mortality reduction of 11% when lisinopril was started within 24 hours of acute MI [5].

The Homocysteine Connection

Many patients prescribed lisinopril carry risk factors that also raise homocysteine. Chronic kidney disease (CKD), diabetes, and advanced age all impair folate handling and raise homocysteine. Because lisinopril is a first-line agent in diabetic nephropathy and CKD, folate deficiency in this group may blunt some of the vascular protection that lisinopril provides. A cross-sectional analysis published in the American Journal of Kidney Diseases (N=985 CKD patients) found that low serum folate was independently associated with a 34% higher odds of elevated homocysteine, even after adjusting for eGFR [6].

ACE Inhibitors and Folate: A Specific Research Thread

One largely overlooked line of research concerns the combination of fosinopril (a related ACE inhibitor) with folic acid in stroke prevention. The CSPPT trial (China Stroke Primary Prevention Trial, N=20,702) randomized hypertensive adults to enalapril 10 mg alone or enalapril 10 mg combined with folic acid 0.8 mg daily. The combination arm reduced first stroke by 21% compared to enalapril monotherapy (hazard ratio 0.79, 95% CI 0.68 to 0.93, P<0.001) [7]. Although enalapril is not lisinopril, both are ACE inhibitors with closely similar mechanisms, and the CSPPT finding is the most direct evidence available that folate co-supplementation may augment ACE-inhibitor therapy rather than interfere with it.

MTHFR Variants and Why They Change the Folate Conversation

What MTHFR Does

The MTHFR enzyme (methylenetetrahydrofolate reductase) converts 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate (5-MTHF), the form of folate that actually donates a methyl group to convert homocysteine back to methionine. Two common single-nucleotide polymorphisms, C677T and A1298C, reduce enzyme activity by roughly 30 to 70% depending on zygosity [8].

Prevalence of MTHFR Variants

Roughly 10 to 15% of North Americans are homozygous for MTHFR C677T (TT genotype), and 40 to 50% carry at least one copy of a variant allele [8]. Among patients with hypertension, the TT genotype has been associated with higher plasma homocysteine and higher cardiovascular event rates in several prospective cohorts.

Choosing the Right Folate Form

Standard folic acid (pteroylglutamic acid) requires reduction and methylation before it becomes biologically active. For individuals with reduced MTHFR activity, conversion is slow and supplemental folic acid may accumulate as unmetabolized folic acid (UMFA) in plasma rather than entering the methylation cycle. The preferred supplemental form for MTHFR variant carriers is L-methylfolate (5-MTHF), which bypasses the MTHFR step entirely. Common commercial doses include 400 mcg, 1 mg, and 15 mg products (Deplin, Metafolin). A 2015 review in Nutrients concluded that 5-MTHF supplementation lowered homocysteine more effectively than folic acid in MTHFR TT homozygotes [9].

If you take lisinopril and have not been tested for MTHFR variants but have a personal or family history of recurrent pregnancy loss, unexplained thrombosis, or early cardiovascular disease, ask your prescriber about MTHFR genotyping. A simple blood or saliva test costs roughly $50, $200 out of pocket.

Folate and Blood Pressure: Does It Help on Its Own?

Epidemiological Evidence

Cross-sectional data from NHANES (N=8,127) published in the American Journal of Epidemiology showed that adults in the highest quartile of dietary folate intake had systolic blood pressure approximately 3.4 mmHg lower than those in the lowest quartile, after adjusting for age, BMI, sodium intake, and physical activity [10]. A 3 to 4 mmHg systolic reduction is clinically meaningful: meta-analyses in hypertension pharmacology estimate that each 2 mmHg reduction in systolic BP lowers stroke risk by roughly 10%.

Randomized Trial Data

A double-blind RCT published in JAMA Internal Medicine (N=180 prehypertensive adults, 24 weeks) tested folic acid 5 mg/day against placebo. Mean systolic BP fell 4.6 mmHg more in the folic acid group (95% CI 1.2 to 8.1 mmHg, P<0.01). The proposed mechanism involves folate-mediated recycling of tetrahydrobiopterin (BH4), a cofactor for endothelial nitric-oxide synthase. When BH4 is depleted, eNOS becomes uncoupled and produces superoxide instead of nitric oxide, driving vasoconstriction [11].

What This Means in Practice

For a patient already on lisinopril with well-controlled blood pressure, adding folate is unlikely to cause hypotension at standard supplemental doses (400 to 800 mcg/day). At pharmacologic doses of 5 mg/day, a modest additive antihypertensive effect is possible. Patients who are borderline hypotensive or who are on multiple antihypertensives should mention any new folate supplement to their prescriber.

Safety Profile: What Risks Actually Exist?

Masking B12 Deficiency

High-dose folic acid (generally above 1 mg/day) can correct the megaloblastic anemia caused by vitamin B12 deficiency without correcting the underlying neurological damage. This is not a lisinopril-specific concern; it applies to folic acid supplementation broadly. The FDA set the tolerable upper intake level (UL) for folic acid at 1,000 mcg (1 mg) per day for adults specifically because of this masking risk [12]. If you are over 50, vegan, or have gastric atrophy, check serum B12 before starting supplemental folic acid above 400 mcg/day.

Renal Excretion and CKD

Lisinopril is commonly prescribed to patients with CKD. Folate is water-soluble and renally excreted, but it does not accumulate toxically in renal impairment at standard supplemental doses. Patients on dialysis actually need supplemental folate because dialysis removes water-soluble vitamins. The National Kidney Foundation's KDOQI guidelines recommend 1 mg folate daily for dialysis patients [13].

Drug-Folate Interactions to Screen for Separately

While folate does not interact with lisinopril specifically, several other medications in a typical hypertension patient's regimen do interact with folate:

• Metformin (common in diabetic hypertension): may reduce serum folate by impairing ileal absorption over time.
• Trimethoprim/sulfamethoxazole (sometimes used in CKD patients for UTI prophylaxis): acts as a folate antagonist.
• Hydrochlorothiazide (sometimes co-prescribed with lisinopril as Zestoretic): no known folate interaction.

Screening the full medication list, not just lisinopril, is the appropriate safety check.

Dosing Framework for Patients on Lisinopril

The following framework reflects the clinical reasoning used by the HealthRX medical team when evaluating folate supplementation for patients already taking lisinopril. It is not a substitute for individualized medical advice.

| Patient Profile | Recommended Folate Form | Suggested Daily Dose | Notes | |---|---|---|---| | General adult, no MTHFR data, no pregnancy | Folic acid | 400 to 800 mcg | Standard multivitamin level; no cardiovascular risk | | Pregnancy or preconception | Folic acid or 5-MTHF | 400 to 800 mcg (low-risk), up to 5 mg if prior neural tube defect | ACOG recommends starting at least 1 month before conception [14] | | MTHFR C677T homozygous (TT) | L-methylfolate (5-MTHF) | 1 to 5 mg | Bypass MTHFR step; confirm B12 adequate | | CKD stage 3 to 5 (not on dialysis) | Folic acid or 5-MTHF | 1 mg | KDOQI-aligned; monitor homocysteine | | On dialysis | Folic acid | 1 mg | KDOQI recommendation [13] | | Elevated homocysteine, cardiovascular history | 5-MTHF preferred | 0.8 to 5 mg | CSPPT-informed approach; discuss with cardiologist [7] | | Post-bariatric surgery | 5-MTHF | 800 mcg to 1 mg | Impaired folic acid absorption common |

Monitoring Recommendations

When to Check Folate Levels

Routine folate monitoring is not required for most patients starting a standard-dose supplement. Testing is warranted if:

• Macrocytic anemia appears on a complete blood count.
• Homocysteine is above 15 micromol/L on a fasting panel.
• Symptoms of deficiency develop (glossitis, fatigue, mood changes).
• The patient is transitioning from a high-dose folic acid to methylfolate due to MTHFR variants.

Homocysteine as a Composite Marker

Plasma homocysteine reflects the adequacy of folate, B12, and B6 together. A fasting homocysteine above 10 micromol/L is considered mildly elevated in cardiovascular risk stratification. The VITATOPS trial (N=8,164) found that B-vitamin supplementation including folic acid 2 mg reduced homocysteine by 2.2 micromol/L compared with placebo at 3.4 years of follow-up [15]. Lisinopril users with elevated homocysteine should discuss a complete B-vitamin panel, not folate in isolation, with their prescriber.

Blood Pressure Monitoring When Starting Pharmacologic Folate Doses

For patients on 5 mg/day folate (a prescription-level dose), checking blood pressure 4 to 6 weeks after starting is reasonable. The 4.6 mmHg systolic reduction seen in [11] is unlikely to cause symptomatic hypotension in most patients, but those with systolic BP already below 110 mmHg or those on three or more antihypertensives should be monitored more closely.

Pregnancy, Preconception, and Lisinopril: A Critical Intersection

Lisinopril is FDA Category D (now described under the 2015 PLLR labeling as causing fetal harm) and must be discontinued as soon as pregnancy is confirmed, ideally before conception [4]. This creates a specific clinical window where folate guidance matters acutely.

Preconception Folate Is Non-Negotiable

ACOG Committee Opinion No. 804 states: "All women planning pregnancy or capable of becoming pregnant should consume 400 to 800 mcg of folic acid daily to reduce the risk of neural tube defects" [14]. For women who have previously had a pregnancy affected by a neural tube defect, 4 mg/day is recommended starting at least 1 month before conception.

If a woman of reproductive age is on lisinopril for hypertension, her prescriber should already be planning the transition to a pregnancy-safe antihypertensive (typically labetalol, nifedipine, or methyldopa). Folate supplementation should begin or be confirmed adequate during that same preconception conversation.

MTHFR and Pregnancy on ACE Inhibitors

Women with MTHFR TT homozygosity who are trying to conceive should use 5-MTHF rather than folic acid, particularly if they have a history of recurrent early pregnancy loss. Because lisinopril must be stopped before conception, the immediate clinical priority is contraception counseling plus folate optimization in the preconception phase, followed by prompt transition to a safer antihypertensive once pregnancy is planned.

What Clinicians and Guidelines Say

The 2023 ACC/AHA Guideline for the Diagnosis and Treatment of Hypertension does not list folate or folic acid as an agent that interacts with ACE inhibitors [16]. The Natural Medicines Database rates the folate-lisinopril combination as "no known interaction" based on available pharmacokinetic and pharmacodynamic data.

Dr. Yue Qi, corresponding author of the CSPPT trial, noted in the JAMA 2015 publication: "In this randomized, double-blind trial, the combined use of enalapril and folic acid, compared with enalapril alone, significantly reduced the risk of first stroke" [7]. While that statement refers to enalapril, the ACE-inhibitor class mechanism is conserved across lisinopril, enalapril, and ramipril, making the finding relevant to lisinopril users.